A medical group in Argentina is asking for more drug-testing regulations in the South American country after a officials fined pharmaceutical company GlaxoSmithKline for alleged irregularities in a pediatric pneumonia vaccine trial.
A Food and Drug Administration committee delivered a split verdict on the diabetes drug Avandia on Wednesday, with most members voting to leave it on the market but recommending different changes in how it's prescribed.
A Food and Drug Administration committee delivered a split verdict on the diabetes drug Avandia on Wednesday, with most members voting to leave it on the market but recommending changes in how it's prescribed.
The diabetes drug Avandia is linked with tens of thousands of heart attacks, and drugmaker GlaxoSmithKline knew of the risks for years but worked to keep them from the public, a Senate committee report released Saturday says.
The diabetes drug Avandia is linked with tens of thousands of heart attacks, and drugmaker GlaxoSmithKline knew of the risks for years but worked to keep them from the public, according to a Senate committee report released Saturday.
Britain plans to force pharmaceutical companies to share more information with regulators about clinical trials after an investigation recently concluded that GlaxoSmithKline PLC deliberately withheld information about an antidepressant
America's 20 million-plus diabetics mean dollar signs for drug companies that sell a slew of new products, including a successful drug based on the saliva of a Gila monster, and a failed inhalation device that's been compared to a "bong."
The controversy surrounding GlaxoSmithKline's diabetes drug Avandia mounted Wednesday as a medical expert prepared to tell lawmakers the British drug maker threatened him with legal action when he first raised questions about the treatment's safety
The recently published study results that link GlaxoSmithKline's blockbuster diabetes drug Avandia to heart attacks could shift market share to rivals Merck, Lilly and Amylin, despite questions surrounding the data, analysts say.
The British drugmaker GlaxoSmithKline is trying wean just a little more revenue from its top-selling blockbuster Advair, and its ability to do so depends on whether FDA experts believe the allergy drug merits a larger patient population.
Besides extra pounds, dieters also seem to carry a hefty independent streak. A survey finds that 70 percent of Americans who are trying to lose weight are following their own diet plans and have no interest in seeking a doctor's help.
GlaxoSmithKline ranks no. 143 on FORTUNE's Global 500 this year, with $39.4 billion in revenues, up 5.5% from the previous year. The Brentford, Britain-based company was ranked no. 122 on the 2005 list. Its 2005 profits were $8.8 billion, up 8.1% from a year earlier. 2005 was a banner year for most Global 500 companies.
Vital protection against cervical cancer could soon be made available, not just from Merck but also from GlaxoSmithKline, providing life-saving potential for women while feeding a competitive atmosphere for the drug giants.
The U.S. Department of Health and Human Services awarded $1 billion to drugmakers, including nearly $700 million to GlaxoSmithKline, Novartis and MedImmune, to help them develop a faster method of producing an influenza vaccine to better protect the nation against the possibility of a pandemic.
GlaxoSmithKline will lose patent protection on a blockbuster migraine treatment in three years, but may have figured out how to protect sales by spinning off the drug as a new combination product, analysts say.
GlaxoSmithKline said it has taken steps to ramp up vaccine production to protect against avian flu following last week's meeting at the White House with President Bush, and other drug giants that participated in the meeting have offered to help.